Is botulinum toxin useful in treating headache? Yes


Opinion statement

Recent scientific data support an effect of botulinum neurotoxin (BoNT) on pain and headache. BoNT was shown to affect the release of neurotransmitters that are important in pain transmission and in migraine pathogenesis. Data from both animal and clinical studies suggest that the toxin may have an analgesic effect that is independent from its effect on muscle tone. The high tolerability and long duration of action of the drug make it appealing as a potential prophylactic treatment for headache patients. Results of controlled trials on the efficacy of BoNT in the treatment of episodic migraine (EM) are mostly negative, although some subgroups of patients (eg, those with high attack frequency) may respond to the drug. Studies of patients with chronic daily headache have been inconclusive, although (as with the EM studies) specific subgroups of patients appear to benefit from the drug. BoNT is probably ineffective for the treatment of chronic tension-type headache. There are anecdotal reports on a positive effect of BoNT in patients with other types of headache (eg, nummular headache). Factors that may affect the response of patients to BoNT include headache characteristics, disease duration, the use of concurrent preventive medications, and the presence or absence of medication overuse. The authors’ clinical experience shows that some headache patients benefit significantly from BoNT treatment. The challenge for future studies is to identify those patients who will best respond to the drug.

References and Recommended Reading

  1. 1.
    Brin MF: Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997, 20:S146–S168.CrossRefGoogle Scholar
  2. 2.
    Binder WJ, Brin MF, Blitzer A, et al.: Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000, 123:669–676.PubMedCrossRefGoogle Scholar
  3. 3.
    Ashkenazi A, Levin M, Dodick DW: Peripheral procedures: nerve blocks, peripheral neurostimulation and botulinum toxin injections. In Wolff’s Headache and Other Head Pain, edn 8. Edited by Silberstein SD, Lipton RB, Dodick DW. New York: Oxford University Press; 2007:767–792.Google Scholar
  4. 4.
    Ashkenazi A, Silberstein SD: Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med 2004, 55:505–518.PubMedCrossRefGoogle Scholar
  5. 5.
    Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43:S109–S115.CrossRefGoogle Scholar
  6. 6.
    Durham PL, Cady R, Cady R: Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004, 44:35–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Silberstein SD, Mathew N, Saper J, Jenkins S: Botulinum toxin type A as a migraine preventive treatment. Headache 2000, 40:445–450.PubMedCrossRefGoogle Scholar
  8. 8.
    Barrientos N, Chana P: Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 2003, 4:146–151.CrossRefGoogle Scholar
  9. 9.
    Evers S, Vollmer-Haase J, Schwaag S, et al.: Botulinum toxin A in the prophylactic treatment of migraine—a randomized, double-blind, placebo-controlled study. Cephalalgia 2004, 24:838–843.PubMedCrossRefGoogle Scholar
  10. 10.
    Saper JR, Mathew NT, Loder EW, et al.: A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med 2007, 8:478–485.PubMedCrossRefGoogle Scholar
  11. 11.
    Elkind AH, O’Carroll P, Blumenfeld A, et al.: A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006, 7:688–696.PubMedCrossRefGoogle Scholar
  12. 12.
    Relja M, Poole AC, Schoenen J, et al.: A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007, 27:492–503.PubMedCrossRefGoogle Scholar
  13. 13.
    Aurora SK, Gawel M, Brandes JL, et al.: Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007, 47:486–499.PubMedCrossRefGoogle Scholar
  14. 14.
    Silberstein SD, Neto W, Schmitt J, Jacobs D: Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. For the MIGR-001 Study Group. Arch Neurol 2004, 61:490–495.PubMedCrossRefGoogle Scholar
  15. 15.
    Freitag FG, Collins SD, Carlson HA, et al.: A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002, 58:1652–1659.PubMedGoogle Scholar
  16. 16.
    Blumenfeld AM, Schim JD, Chippendale TJ: Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008, 48:210–220.PubMedGoogle Scholar
  17. 17.
    Dodick DW: Clinical practice. Chronic daily headache. N Engl J Med 2006, 354:158–165.PubMedCrossRefGoogle Scholar
  18. 18.
    Ondo WG, Vuong KD, Derman HS: Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004, 24:60–65.PubMedCrossRefGoogle Scholar
  19. 19.
    Mathew NT, Frishberg BM, Gawel M, et al.: Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005, 45:293–307.PubMedCrossRefGoogle Scholar
  20. 20.
    Dodick DW, Mauskop A, Elkind AH, et al.: Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005, 45:315–324.PubMedCrossRefGoogle Scholar
  21. 21.
    Silberstein SD, Stark SR, Lucas SM, et al.: Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:1126–1137.PubMedCrossRefGoogle Scholar
  22. 22.
    Freitag FG, Diamond S, Diamond M, Urban G: Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008, 48:201–209.PubMedGoogle Scholar
  23. 23.
    Schulte-Mattler WJ, Krack P: Treatment of chronic tensiontype headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004, 109:110–114.PubMedCrossRefGoogle Scholar
  24. 24.
    Silberstein SD, Gobel H, Jensen R, et al.: Botulinum toxin type A in the prophylactic treatment of chronic tensiontype headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006, 26:790–800.PubMedCrossRefGoogle Scholar
  25. 25.
    Padberg M, de Bruijn SF, de Haan RJ, Tavy DL: Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004, 24:675–680.PubMedCrossRefGoogle Scholar
  26. 26.
    Schmitt WJ, Slowey E, Fravi N, et al.: Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001, 41:658–664.PubMedCrossRefGoogle Scholar
  27. 27.
    Rollnik JD, Tanneberger O, Schubert M, et al.: Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 2000, 40:300–305.PubMedCrossRefGoogle Scholar
  28. 28.
    Pareja JA, Pareja J, Barriga FJ, et al.: Nummular headache: a prospective series of 14 new cases. Headache 2004, 44:611–614.PubMedCrossRefGoogle Scholar
  29. 29.
    Mathew NT, Kailasam J, Meadors L: Botulinum toxin type A for the treatment of nummular headache: four case studies. Headache 2008, 48:442–447.PubMedCrossRefGoogle Scholar
  30. 30.
    Dolly O: Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003, 43(Suppl 1):S16–S24.PubMedCrossRefGoogle Scholar
  31. 31.
    Cui M, Khanijou S, Rubino J, Aoki KR: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125–133.PubMedCrossRefGoogle Scholar
  32. 32.
    Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38:245–258.PubMedCrossRefGoogle Scholar
  33. 33.
    McMahon HT, Foran P, Dolly JO, et al.: Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and metenkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem 1992, 267:21338–21343.PubMedGoogle Scholar
  34. 34.
    Oshinsky ML: Botulinum toxins and migraine: how does it work? Pract Neurol 2004, 4(Suppl):10–13.Google Scholar
  35. 35.
    Antonucci F, Rossi C, Gianfranceschi L, et al.: Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008, 28:3689–3696.PubMedCrossRefGoogle Scholar
  36. 36.
    Jakubowski M, McAllister PJ, Bajwa ZH, et al.: Exploding vs. imploding headache in migraine prophylaxis with Botulinum toxin A. Pain 2006, 125:286–295.PubMedCrossRefGoogle Scholar
  37. 37.
    Mathew NT, Kailasam J, Meadors L: Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008, 48:194–200.PubMedGoogle Scholar
  38. 38.
    Eross EJ, Gladstone JP, Lewis S, et al.: Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005, 45:308–314.PubMedCrossRefGoogle Scholar
  39. 39.
    Bendtsen L, Mattsson P, Zwart JA, Lipton RB: Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003, 23:487–490.PubMedCrossRefGoogle Scholar
  40. 40.
    Loder E, Goldstein R, Biondi D: Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia 2005, 25:124–131.PubMedCrossRefGoogle Scholar
  41. 41.
    Schwedt TJ, Hentz JG, Dodick DW: Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine. Cephalalgia 2007, 27:528–534.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of NeurologyThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations